Seer offers tools and solutions that provide unbiased, deep, rapid and large-scale proteomics in the field of biotechnology. More specifically, Seer's life sciences and health data platform helps detect life-threatening diseases before symptoms start to show. The company claims to be able to analyze protein composition in a comparable way to sequencing machines ‘reading’ strands of DNA.
Seer has grown rapidly: the company went public in 2020 after being founded in 2017, and enjoys strong financial backing that has helped it launch a varied range of proteomics products.
Seer faces competition from the likes of Nautilus and Illumina, a multibillion giant in the sequencing world, who have a sub-division dedicated to proteomics. However, Seer has featured on the Deloittes Fast500 2023 and won multiple awards for its innovative product, putting it in good stead to grow rapidly.
Steph
Company Specialist at Welcome to the Jungle